Literature DB >> 18522246

Sustained analgesic peptide secretion and cell labeling using a novel genetic modification.

Shyam Gajavelli1, Daniel A Castellanos, Orion Furmanski, Paul C Schiller, Jacqueline Sagen.   

Abstract

Cell-based therapy for neuropathic pain could provide analgesics to local pain modulatory regions in a sustained, renewable fashion. In order to provide enhanced analgesic efficacy, transplantable cells may be engineered to produce complementary or increased levels of analgesic peptides. In addition, genetic labeling of modified cells is desirable for identification and tracking, but it should be retained intracellularly as desired analgesic peptides are secreted. Usually constructs encode proteins destined for either extra- or intracellular compartments, as these pathways do not cross. However, interactions between intracellular destinations provide a window of opportunity to overcome this limitation. In this report, we have explored this approach using a potential supplementary analgesic peptide, [Ser1]-histogranin (SHG), the stable synthetic derivative of a naturally occurring peptide with N-methyl D-aspartate (NMDA) antagonistic properties. A synthetic SHG gene was combined with (i) nerve growth factor-beta (NGF-beta) amino-terminal signal peptide to enable secretion, and (ii) a fluorescent cellular label (mRFP) with intervening cathepsin L cleavage site, and subcloned into a lentiviral vector. In addition, an endoplasmic retention signal, KDEL, was added to enable retrieval of mRFP. Using immunocytochemistry and confocal microscopic profile analysis, cells transduced by such lentiviruses were shown to synthesize a single SHG-mRFP polypeptide that was processed, targeted to expected subcellular destinations in several cell types. Dot blot and Western analysis revealed stable transduction and long-term secretion of SHG from PC12 cells in vitro. Transplantation of such cells provided modest analgesia in a rodent pain model consistent with low levels of SHG peptide in the cerebrospinal fluid (CSF). These results suggest that it is possible to deliver proteins with different final destinations from a single construct, such as pharmacologically active peptide for secretion and intracellular label for identifying transplantable cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18522246      PMCID: PMC2743252     

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  44 in total

1.  Isolation of liver and muscle polyribosomes in high yield after cell disruption by nitrogen cavitation.

Authors:  R M. Dowben; A Gaffey; P M. Lynch
Journal:  FEBS Lett       Date:  1968-11       Impact factor: 4.124

2.  A hexahistidine-Zn2+-dye label reveals STIM1 surface exposure.

Authors:  Christina T Hauser; Roger Y Tsien
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-28       Impact factor: 11.205

3.  Fluorescence protease protection of GFP chimeras to reveal protein topology and subcellular localization.

Authors:  Holger Lorenz; Dale W Hailey; Jennifer Lippincott-Schwartz
Journal:  Nat Methods       Date:  2006-03       Impact factor: 28.547

4.  Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture.

Authors:  Y Wang; D L Huso; J Harrington; J Kellner; D K Jeong; J Turney; I K McNiece
Journal:  Cytotherapy       Date:  2005       Impact factor: 5.414

5.  NMDA antagonist peptide supplementation enhances pain alleviation by adrenal medullary transplants.

Authors:  Farinaz NasiriNezhad; Jacqueline Sagen
Journal:  Cell Transplant       Date:  2005       Impact factor: 4.064

6.  Grafts of immortalized chromaffin cells bio-engineered to improve met-enkephalin release also reduce formalin-evoked c-fos expression in rat spinal cord.

Authors:  H Duplan; R Y Li; C Vue; H Zhou; L Emorine; J P Herman; M Tafani; Y Lazorthes; M J Eaton
Journal:  Neurosci Lett       Date:  2004-11-03       Impact factor: 3.046

7.  Isolation and characterization of histogranin, a natural peptide with NMDA receptor antagonist activity.

Authors:  S Lemaire; V K Shukla; C Rogers; I H Ibrahim; C Lapierre; P Parent; M Dumont
Journal:  Eur J Pharmacol       Date:  1993-05-15       Impact factor: 4.432

8.  Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter.

Authors:  Sukkid Yasothornsrikul; Doron Greenbaum; Katalin F Medzihradszky; Thomas Toneff; Richard Bundey; Ruthellen Miller; Birgit Schilling; Ivonne Petermann; Jessica Dehnert; Anna Logvinova; Paul Goldsmith; John M Neveu; William S Lane; Bradford Gibson; Thomas Reinheckel; Christoph Peters; Matthew Bogyo; Vivian Hook
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

9.  Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector.

Authors:  Andrea L Szymczak; Creg J Workman; Yao Wang; Kate M Vignali; Smaroula Dilioglou; Elio F Vanin; Dario A A Vignali
Journal:  Nat Biotechnol       Date:  2004-04-04       Impact factor: 54.908

10.  Localization of the Lys, Asp, Glu, Leu tetrapeptide receptor to the Golgi complex and the intermediate compartment in mammalian cells.

Authors:  G Griffiths; M Ericsson; J Krijnse-Locker; T Nilsson; B Goud; H D Söling; B L Tang; S H Wong; W Hong
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

View more
  7 in total

1.  Combined extrinsic and intrinsic manipulations exert complementary neuronal enrichment in embryonic rat neural precursor cultures: an in vitro and in vivo analysis.

Authors:  Orion Furmanski; Shyam Gajavelli; Jeung Woon Lee; Maria E Collado; Stanislava Jergova; Jacqueline Sagen
Journal:  J Comp Neurol       Date:  2009-07-01       Impact factor: 3.215

2.  Review of the history and current status of cell-transplant approaches for the management of neuropathic pain.

Authors:  Mary J Eaton; Yerko Berrocal; Stacey Q Wolfe; Eva Widerström-Noga
Journal:  Pain Res Treat       Date:  2012-06-14

3.  Viral vectors encoding endomorphins and serine histogranin attenuate neuropathic pain symptoms after spinal cord injury in rats.

Authors:  Farinaz Nasirinezhad; Shyam Gajavelli; Blake Priddy; Stanislava Jergova; James Zadina; Jacqueline Sagen
Journal:  Mol Pain       Date:  2015-01-07       Impact factor: 3.395

4.  Experimental Gene Therapy with Serine-Histogranin and Endomorphin 1 for the Treatment of Chronic Neuropathic Pain.

Authors:  Stanislava Jergova; Catherine E Gordon; Shyam Gajavelli; Jacqueline Sagen
Journal:  Front Mol Neurosci       Date:  2017-12-08       Impact factor: 5.639

5.  Analgesic effect of recombinant GABAergic precursors releasing ω-conotoxin MVIIA in a model of peripheral nerve injury in rats.

Authors:  Stanislava Jergova; Melissa Hernandez; Jacqueline Sagen
Journal:  Mol Pain       Date:  2022-04       Impact factor: 3.370

6.  Recombinant neural progenitor transplants in the spinal dorsal horn alleviate chronic central neuropathic pain.

Authors:  Stanislava Jergova; Shyam Gajavelli; Nirmal Pathak; Jacqueline Sagen
Journal:  Pain       Date:  2016-04       Impact factor: 7.926

7.  Simultaneous intrathecal injection of muscimol and endomorphin-1 alleviates neuropathic pain in rat model of spinal cord injury.

Authors:  Marjan Hosseini; Zohreh Karami; Mahmood Yousefifard; Atousa Janzadeh; Elham Zamani; Farinaz Nasirinezhad
Journal:  Brain Behav       Date:  2020-03-18       Impact factor: 2.708

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.